Adherence to osteoporosis treatments: Room for improvement

Current Opinion in Rheumatology

Volumn 21, Issue 4, 2009, Pages 356-362

  Warriner, Amy H ^a   Curtis, Jeffrey R ^a,b  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b FOT 840 ^*  (United States)

Author keywords

Adherence; Bisphosphonate; Compliance; Medication; Osteoporosis

Indexed keywords

ALENDRONIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCIUM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IBANDRONIC ACID; PLACEBO; RALOXIFENE; RISEDRONIC ACID; VITAMIN D; ZOLEDRONIC ACID;

BONE DENSITY; BONE TURNOVER; CLINICAL FEATURE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DISEASE COURSE; DOCTOR PATIENT RELATION; DRUG COST; DRUG EFFICACY; DRUG MONITORING; DRUG SAFETY; DRUG TOLERABILITY; DUAL ENERGY X RAY ABSORPTIOMETRY; ESTROGEN THERAPY; FEEDBACK SYSTEM; FRACTURE; HEALTH BEHAVIOR; HEALTH CARE COST; HEALTH CARE PERSONNEL; HIP FRACTURE; HUMAN; MEDICARE; MORBIDITY; OSTEOPOROSIS; PATIENT COMPLIANCE; PATIENT EDUCATION; PRIORITY JOURNAL; REIMBURSEMENT; REVIEW; RISK REDUCTION; SELF REPORT; VITAMIN SUPPLEMENTATION;

BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; DRUG ADMINISTRATION SCHEDULE; FRACTURES, BONE; HUMANS; OSTEOPOROSIS; PATIENT COMPLIANCE; PATIENT EDUCATION AS TOPIC; PHYSICIAN-PATIENT RELATIONS; PSYCHOLOGY; RISK REDUCTION BEHAVIOR;

EID: 67149101339     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/BOR.0b013e32832c6aa4     Document Type: Review

References (47)

1. Burge R, Dawson-Hughes B, Solomon DH, et al. Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025. J Bone Miner Res 2007; 22:465-475.
2. Cramer JA, Amonkar MM, Hebborn A, Altman R. Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. Curr Med Res Opin 2005; 21:1453-1460. (Pubitemid 41368578)
3. Cramer JA, Silverman S. Persistence with bisphosphonate treatment for osteoporosis: finding the root of the problem. Am J Med 2006; 119 (4 Suppl 1): S12-S17.
4. Weycker D, Macarios D, Edelsberg J, Oster G. Compliance with drug therapy for postmenopausal osteoporosis. Osteoporos Int 2006; 17:1645-1652. (Pubitemid 44477625)
5. Miller NH. Compliance with treatment regimens in chronic asymptomatic diseases. Am J Med 1997; 102:43-49. (Pubitemid 27147947)
6. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005; 353:487-497. (Pubitemid 41127293)
7. Cramer JA, Roy A, Burrell A, et al. Medication compliance and persistence: terminology and definitions. Value Health 2008; 11:44-47. This article defines the terms used for medication compliance. Consistent definitions of terms related to compliance are needed for comparability in assessing results across studies. (Pubitemid 351160875)
8. Kothawala P, Badamgarav E, Ryu S, et al. Systematic review and meta-analysis of real-world adherence to drug therapy for osteoporosis. Mayo Clin Proc 2007; 82:1493-1501. This meta-analysis of osteoporosis treatment adherence from 1990 to 2006 combines results from various studies to provide summary results pertaining to compliance, persistence, and adherence. (Pubitemid 350211697)
9. Lekkerkerker F, Kanis JA, Alsayed N, et al. Adherence to treatment of osteoporosis: a need for study. Osteoporos Int 2007; 18:1311-1317.
10. Garber MC, Nau DP, Erickson SR, et al. The concordance of self-report with other measures of medication adherence: a summary of the literature. Med Care 2004; 42:649-652.
11. Brookhart MA, Avorn J, Katz JN, et al. Gaps in treatment among users of osteoporosis medications: the dynamics of noncompliance. Am J Med 2007; 120:251-256. (Pubitemid 46341156)
12. McHorney CA, Schousboe JT, Cline RR, Weiss TW. The impact of osteoporosis medication beliefs and side-effect experiences on nonadherence to oral bisphosphonates. Curr Med Res Opin 2007; 23:3137-3152.
13. Cook PF, Emiliozzi S, McCabe MM. Telephone counseling to improve osteoporosis treatment adherence: an effectiveness study in community practice settings. Am J Med Qual 2007; 22:445-456.
14. Lau E, Papaioannou A, Dolovich L, et al. Patients' adherence to osteoporosis therapy: exploring the perceptions of postmenopausal women. Can Fam Physician 2008; 54:394-402. Thirty-seven postmenopausal women on osteoporosis treatment were questioned in a focus group setting regarding their perspectives on osteoporosis treatment adherence and methods for improving adherence.
15. Curtis JR, Westfall AO, Cheng H, et al. Benefit of adherence with bisphosphonates depends on age and fracture type: results from an analysis of 101,038 new bisphosphonate users. J Bone Miner Res 2008; 23:1435-1441. This study was one among several that has evaluated the effect of medication adherence and fracture risk. Among its unique results, it showed that the relationship between osteoporosis medication adherence and fracture risk varied significantly by the type of fracture and age.
16. Curtis JR, Laster AJ, Becker DJ, et al. Regional variation in the denial of reimbursement for bone mineral density testing among US Medicare beneficiaries. J Clin Densitom 2008; 11:568-574. This study evaluated reasons for denial of DXA reimbursement. The reasons found for denial varied depending on age, sex, time since last DXA, International Classification of Diseases-9 codes, among other factors.
17. FRAX WHO fracture risk assessment tool. http://www.shef.ac.uk/FRAX/. [Accessed 2 February 2009]. The FRAX calculator allows determination of 10-year absolute fracture risk estimates based on BMD and multiple clinical risk factors for fracture. The fracture risks computed from FRAX have been used by various groups to guide recommendations for use of prescription osteoporosis treatments.
18. Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001; 23:1296-1310. (Pubitemid 32804122)
19. Payer J, Killinger Z, Sulkova I, Celec P. Preferences of patients receiving bisphosphonates: how to influence the therapeutic adherence. Biomed Pharmacother 2008; 62:122-124. Through the use of a questionnaire, osteoporosis medication preferences were determined in a Slovakian population. (Pubitemid 351215813)
20. Emkey R, Koltun W, Beusterien K, et al. Patient preference for once-monthly ibandronate versus once-weekly alendronate in a randomized, open-label, cross-over trial: the Boniva Alendronate Trial in Osteoporosis (BALTO). Curr Med Res Opin 2005; 21:1895-1903. (Pubitemid 41803098)
21. Kastelan D, Lozo P, Stamenkovic D, et al. Preference for weekly and monthly bisphosphonates among patients with postmenopausal osteoporosis: results from the Croatian PROMO Study. Clin Rheumatol 2009; 28:321-326. In this study from Croatia, women treated with weekly osteoporosis therapy were switched to once-monthly ibandronate. At the end of the study, approximately 95% of the patients stated that they preferred the once-monthly preparation.
22. Lo JC, Pressman AR, Omar MA, Ettinger B. Persistence with weekly alendronate therapy among postmenopausal women. Osteoporos Int 2006; 17:922-928. (Pubitemid 43781507)
23. Solomon DH, Avorn J, Katz JN, et al. Compliance with osteoporosis medications. Arch Intern Med 2005; 165:2414-2419.
24. Curtis JR, Xi J, Westfall AO, et al. Improving the prediction of medication compliance: the example of bisphosphonates for osteoporosis. Med Care 2009; 47:334-341. This study determined that evaluating a patient's adherence to medications for other asymptomatic chronic diseases (e.g. hyperlipidemia) improves the prediction of osteoporosis treatment adherence.
25. Yood RA, Emani S, Reed JI, et al. Compliance with pharmacologic therapy for osteoporosis. Osteoporos Int 2003; 14:965-968. (Pubitemid 40824268)
26. Clowes JA, Peel NF, Eastell R. The impact of monitoring on adherence and persistence with antiresorptive treatment for postmenopausal osteoporosis: a randomized controlled trial. J Clin Endocrinol Metab 2004; 89:1117-1123. (Pubitemid 38368399)
27. Siris ES, Harris ST, Rosen CJ, et al. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc 2006; 81:1013-1022.
28. Weycker D, Macarios D, Edelsberg J, Oster G. Compliance with osteoporosis drug therapy and risk of fracture. Osteoporos Int 2007; 18:271-277. (Pubitemid 46233172)
29. Rabenda V, Mertens R, Fabri V, et al. Adherence to bisphosphonates therapy and hip fracture risk in osteoporotic women. Osteoporos Int 2008; 19:811-818. This study evaluated the risk of hip fracture on the basis of osteoporosis medication adherence in a Belgian population and found a significant correlation.
30. Penning-van Beest FJ, Erkens JA, Olson M, Herings RM. Loss of treatment benefit due to low compliance with bisphosphonate therapy. Osteoporos Int 2008; 19:511-517. This study evaluated differences in fracture risk reduction in new bisphosphonate users. As adherence improves, there is a significant reduction in osteoporotic fracture risk.
31. Stephenson J. Noncompliance may cause half of antihypertensive drug 'failures'. JAMA 1999; 282:313-314.
32. Bone HG, Hosking D, Devogelaer JP, et al. Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 2004; 350:1189-1199. (Pubitemid 38339363)
33. Curtis JR, Westfall AO, Cheng H, et al. Risk of hip fracture after bisphosphonate discontinuation: implications for a drug holiday. Osteoporos Int 2008; 19:1613-1620. This study evaluated fracture risk following discontinuation of a bisphosphonate. Women who took bisphosphonates at least 66% of the time for at least 2 years were at increased risk of hip fracture after subsequent discontinuation. However, those more compliant and those who continued treatment for more than 2 years were not at significantly increased risk, suggesting the possibility that a temporary 'drug holiday' after several years of compliance may be well tolerated.
34. Watts NB, Chines A, Olszynski WP, et al. Fracture risk remains reduced one year after discontinuation of risedronate. Osteoporos Int 2008; 19:365-372. This study evaluated the risk of vertebral fracture in women who had taken bisphosphonates for 3 years and then discontinued. Despite reduction in BMD, risk of vertebral fracture was not significantly increased 1 year after discontinuation. (Pubitemid 351199181)
35. Centers for Disease Control and Prevention (CDC). Fatalities and injuries from falls among older adults: United States, 1993-2003 and 2001-2005. MMWR Morb Mortal Wkly Rep 2006; 55:1221-1224.
36. Strom O, Borgstrom F, Kanis JA, Jonsson B. Incorporating adherence into health economic modelling of osteoporosis. Osteoporos Int 2009; 20:23-34. This study discusses the health benefits vs. increased healthcare costs using two theoretical medication options to examine the effect of improved adherence but increased cost that some medication options pose.
37. Sunyecz JA, Mucha L, Baser O, et al. Impact of compliance and persistence with bisphosphonate therapy on healthcare costs and utilization. Osteoporos Int 2008; 19:1421-1429. This 3-year study found that women who were adherent with osteoporosis therapies had lower healthcare costs than those who were nonadherent.
38. Influence of adherence to treatment and response of cholesterol on mortality in the coronary drug project. N Engl J Med 1980; 303:1038-1041.
39. Granger BB, Swedberg K, Ekman I, et al. Adherence to candesartan and placebo and outcomes in chronic heart failure in the CHARM programme: double-blind, randomised, controlled clinical trial. Lancet 2005; 366:2005-2011. (Pubitemid 41773375)
40. Horwitz RI, Viscoli CM, Berkman L, et al. Treatment adherence and risk of death after a myocardial infarction. Lancet 1990; 336:542-545. (Pubitemid 20278106)
41. Guilera M, Fuentes M, Grifols M, et al. Does an educational leaflet improve self-reported adherence to therapy in osteoporosis? The OPTIMA study. Osteoporos Int 2006; 17:664-671.
42. Nattras S, Silverman S, Drinkwater B. Effectiveness of education and/or NTx results as a means of encouraging compliance to alendronate. Presented at World Congress on Osteoporosis; 15-18 June 2000; Chicago, Illinois; 2000.
43. Delmas PD, Vrijens B, Eastell R, et al. Effect of monitoring bone turnover markers on persistence with risedronate treatment of postmenopausal osteoporosis. J Clin Endocrinol Metab 2007; 92:1296-1304.
44. Lewiecki EM, Babbitt AM, Piziak VK, et al. Adherence to and gastrointestinal tolerability of monthly oral or quarterly intravenous ibandronate therapy in women with previous intolerance to oral bisphosphonates: a 12-month, open-label, prospective evaluation. Clin Ther 2008; 30:605-621. In this study, 543 women with osteoporosis or osteopenia were allowed to choose either a monthly oral bisphosphonate or an intravenous bisphosphonate dosed quarterly. When given this option, adherence to treatment improved.
45. Pickney CS, Arnason JA. Correlation between patient recall of bone densitometry results and subsequent treatment adherence. Osteoporos Int 2005; 16:1156-1160. (Pubitemid 41225103)
46. Cooper A, Drake J, Brankin E. Treatment persistence with once-monthly ibandronate and patient support vs. once-weekly alendronate: results from the PERSIST study. Int J Clin Pract 2006; 60:896-905. (Pubitemid 44082279)
47. Silverman S. Adherence to medications for the treatment of osteoporosis. Rheum Dis Clin North Am 2006; 32:721-731. (Pubitemid 46613878)